Introduction
Rel/NF-kB transcription factors include a collection of proteins, conserved from Drosophila to humans ( Figure  1) . Among model organisms, these transcription factors are notably absent in yeast and C. elegans; in part, this may be because one of the primary roles of these factors is to control a variety of physiological aspects of immune and in¯ammatory responses. A pathway similar to the Rel/NF-kB signaling pathway may also control certain defense responses in plants.
The Rel/NF-kB proteins are related through a highly conserved DNA-binding/dimerization domain called the Rel homology (RH) domain. However, they can be divided into two classes based on sequences Cterminal to the RH domain. Members of one class (p105, p100, and Drosophila Relish) have long Cterminal domains that contain multiple copies of ankyrin repeats, which act to inhibit these molecules. Members of this class become active, shorter DNAbinding proteins (p105 to p50, p100 to p52) by either limited proteolysis or arrested translation. As such, members of this ®rst class are generally not activators of transcription, except when they form dimers with members of the second class of Rel/NF-kB transcription factors. The second class includes c-Rel (and its homologue v-Rel), RelB, RelA (p65), Dorsal, and Dif. These Rel proteins contain C-terminal activation domains, which are often not conserved at the sequence level across species, even though they can activate transcription in a variety of species.
Rel/NF-kB transcription factors bind to 10 base pair DNA sites (kB sites) as dimers. All vertebrate Rel proteins can form homodimers or heterodimers, except for RelB, which can only form heterodimers. This combinatorial diversity contributes to the regulation of distinct, but overlapping, sets of genes, in that the individual dimers have distinct DNA-binding site speci®cities for a collection of related kB sites. NFkB commonly refers to a p50-RelA heterodimer, which is one of the most avidly forming dimers and is the major Rel complex in most cells.
The activity of NF-kB is tightly regulated by interaction with inhibitory IkB proteins. As with the Rel/NF-kB proteins, there are several IkB proteins (see Karin, 1999) , which have dierent anities for individual Rel/NF-kB complexes, are regulated slightly dierently, and are expressed in a tissuespeci®c manner. The best-studied Rel-IkB interaction is that of IkBa with NF-kB, and this interaction blocks the ability of NF-kB to enter the nucleus and bind to DNA. From biochemical studies and, more recently, direct structural determinations (Chen and Ghosh, 1999) , it is clear that IkBa makes multiple contacts with NF-kB. These interactions cover the nuclear localization sequence of NF-kB and interfere with sequences important for DNA binding.
Thus, in most cells, NF-kB is present as a latent, inactive, IkB-bound complex in the cytoplasm. When a cell receives any of a multitude of extracellular signals (see Pahl, 1999) , NF-kB rapidly enters the nucleus and activates gene expression. Thus, a key step for controlling NF-kB activity is the regulation of the IkB-NF-kB interaction. Many of the molecular details of this control are now understood (see Karin, 1999; Figure 2) . Almost all signals that lead to activation of NF-kB converge on a high molecular weight complex that contains a serine-speci®c IkB kinase (IKK). The IKK is an unusual kinase in that it contains two related kinases, IKKa and IKKb, that are active as a dimer. Activation of IKK leads to the phosphorylation of two speci®c serines near the N terminus of IkBa, which targets IkBa for ubiquitination and degradation by the proteasome. The unmasked NF-kB can then enter the nucleus to activate target gene expression. One of the target genes activated by NF-kB is that encoding IkBa. Newly-synthesized IkBa can enter the nucleus, remove NF-kB from DNA, and export the complex back to the cytoplasm to restore the original latent state.
Organization of this collection of reviews
The Rel/NF-kB family is arguably the most-studied collection of eukaryotic transcription factors. As such, the choice of subjects to review was daunting. Because this is a journal dedicated to the control of cell growth and oncogenesis, I decided to make the role of Rel/NFkB in these processes the focus of this issue. Nevertheless, to set the stage, it was necessary to include several introductory articles on structure (Chen and Ghosh, 1999), activators and target genes (Pahl, 1999) , intracellular activation of the Rel/NF-kB signal transduction pathway (Karin, 1999) , and the genetics of Rel/NF-kB signaling in Drosophila (Govind, 1999) and mice (Gerondakis et al., 1999 ). The focus on oncogenesis then ensues. In the same way that there are myriad activators of this pathway, Epinat and Gilmore, 1999 have unearthed an extensive collection of inhibitors of Rel/NF-kB signaling, some of which may eventually prove important for the treatment of human cancers. In the last 4 years there has been great interest in the role of Rel/NF-kB transcription factors in controlling apoptosis. However, this has quickly *Correspondence: TD Gilmore Oncogene (1999) 18, 6842 ± 6844 ã 1999 Stockton Press All rights reserved 0950 ± 9232/99 $15.00 http://www.stockton-press.co.uk/onc become a quite complex subject, as Rel/NF-kB transcription factors have both pro-apoptotic and anti-apoptotic eects (Barkett and Gilmore, 1999) . Following this, there is a review on the avian retroviral oncoprotein v-Rel (Gilmore, 1999) , which is still the only convenient model system for studying Rel-mediated oncogenesis. The issue concludes with three chapters detailing roles for Rel/NF-kB signaling in human oncogenesis. First, Rayet and GeÂ linas, 1999 describe the many genetic alterations in Rel/NF-kB and IkB genes that have been found in human cancers.
Finally, there are two chapters that describe the role of Rel/NF-kB signaling in viral leukemogenesis caused by human T-lymphotropic virus type 1 (HTLV-1) (Sun and Ballard, 1999) and Epstein-Barr virus (EBV) (Cahir McFarland et al., 1999) .
The future: unresolved questions
Our extensive knowledge of Rel/NF-kB signaling betrays also our profound ignorance. We still have very little appreciation for the in vivo dynamics of this pathway. For example, in most cell types and signaling conditions, it is still not known what is the contribution of speci®c Rel/NF-kB complexes (p50-RelA vs p52-c-Rel vs c-Rel-c-Rel) to a given physiological response. Over-expression studies in tissue culture almost certainly do not accurately reflect physiological signaling events. Similarly, what controls the balance between the levels of the various heterodimeric complexes in vivo is not known. Studies in Drosophila have elegantly shown that very small dierences in nuclear concentrations of these factors, in anities for target DNA sites, and in cooperation or competition between Rel proteins and other transcription factors can have profound physiological consequences in organisms (see Govind, 1999) . Lastly, in many situations, it is not known how or which of the many genes induced by Rel/NF-kB factors in a given response contribute to that response. One wonders whether the ability to analyse genome-wide changes in gene expression, which will unquestionably uncover additional Rel/NF-kB-responsive genes, will clarify this situation or muddle it further.
The structures of several Rel/NF-kB dimers on DNA or bound to IkB are now known (Chen and Ghosh, 1999) . In all cases, these structures have been derived from molecules that contain almost exclusively residues from the RH domain. As such, these studies provide rather static glimpses of these factors. Several molecular and biochemical studies indicate that Rel dimers assume distinct conformations when bound to DNA versus as free or IkB-bound dimers or when bound to dierent kB sites. Moreover, such studies have also indicated that C-terminal sequences in¯uence sequences within the RH domain. Furthermore, there is little information about how any of the Rel/NF-kB complexes actually activate transcription; that is, what are the co-activators or basal factors with which they interact to activate transcription. Therefore, we cannot accurately simulate the dynamic nature of the complex as it releases from IkB, enters the nucleus, binds to DNA, and enhances gene expression.
Although the discovery and characterization of the IkB kinase complex is a monumental step in our understanding of the regulation of this pathway, it has opened up more questions than it has answered. It is not known precisely which proteins are in this complex, the exact size of the complex, whether the IKK complex has substrates other than IkB (almost certainly), how the various pathways converge on IKK (for example, what and how many upstream kinases can activate IKK), how one subunit of this complex (IKKa) controls a speci®c developmental process such as keratinocyte dierentiation, and what other signaling pathways may crosstalk via IKK.
The study of v-Rel unequivocably demonstrates that Rel/NF-kB transcription factors can be oncogenic, and one would like to know how the activating mutations in v-Rel have altered its structure as compared to cRel. However, v-Rel has accumulated so many activating mutations (Gilmore, 1999 ) that it may not be a precise model for the role of these transcription factors in human cancers, where a single mutation has occurred. Thus, it is not known whether the rearrangements, mutations, and ampli®cations in Rel/ NF-kB/IkB genes that have been identi®ed in several human cancers and the constitutive NF-kB signaling seen in certain human cancers or induced by oncogenic human viruses (e.g., EBV and HTLV-1) contribute to proliferation, abrogate growth suppression, or influence the control of apoptosis.
The involvement of Rel/NF-kB transcription factors in human in¯ammation and disease certainly sets them up as targets for therapeutics. Indeed, many common synthetic (e.g., aspirin), and traditional (e.g., green tea, curcumin) remedies target, at least in part, the Rel/NFkB signaling pathway (Epinat and Gilmore, 1999) . Will our knowledge of the molecular details of this pathway enable us to develop more speci®c and potent inhibitors?
A revised nomenclature for members of the Rel/NF-kB signal transduction pathway Among the many publications on this topic, there are inconsistencies in the naming of genes and proteins in the Rel/NF-kB pathway. Although a system of nomenclature for the Rel/NF-kB transcription factors and IkB proteins was established previously (Nabel and Verma, 1993) , I have used and propose a slightly modi®ed nomenclature (Table 1 ). The revised nomenclature re¯ects the new members of this pathway, common usage over the past several years, and at times my own judgment. In most cases, the choice was quite simple, although the p65 vs RelA decision continues to be a thorny one; (even though the p65 habit is hard to break, RelA is much more consistent and logical). 
